scholarly journals Concomitant Medication Class

2020 ◽  
Author(s):  
Keyword(s):  
Concomitant Medication ◽  
Medication Class

The Effects of Molindone as a Concomitant Medication on Aggressive Behavior

2010 ◽  
Vol 3 (4) ◽  
pp. 193-200
Author(s):  
J. Lindenmayer ◽  
Frances Alcantara ◽  
Anzalee Khan ◽  
Michael Ciranni
Keyword(s):  
Aggressive Behavior ◽  
Concomitant Medication

AB0402 Concomitant medication frequency and profiles in a real-life canadian cohort of RA patients treated with infliximab

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 660.12-660
Author(s):  
M. Khraishi ◽  
D. Choquette ◽  
E. Rampakakis ◽  
J. Sampalis ◽  
S. Otawa ◽  
...  
Keyword(s):  
Concomitant Medication ◽  
Real Life

scholarly journals Surveillance of Adverse Drug Events Associated with Tocilizumab in Hospitalized Veterans with COVID-19 to Inform Patient Safety and Pandemic Preparedness

2021 ◽  
pp. 1-12
Author(s):  
Rupak Datta ◽  
Alexis Barrett ◽  
Muriel Burk ◽  
Cedric Salone ◽  
Anthony Au ◽  
...  
Keyword(s):  
Patient Safety ◽  
Median Time ◽  
Concomitant Medication ◽  
Chart Review ◽  
Adverse Drug Events ◽  
National Sample ◽  
Pandemic Preparedness ◽  
Medication Discontinuation

Abstract We evaluated adverse drug events (ADE) by chart review in a random national sample of 428 Veterans with COVID-19 who received tocilizumab (n=173/428). ADEs (median time=5 days) occurred in 51/173 (29%) and included hepatoxicity (n=29) and infection (n=13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.

scholarly journals Effects of eplerenone on resistance to antihypertensive medication in patients with primary or secondary hyperaldosteronism

2017 ◽  
Vol 5 (2) ◽  
pp. 93-99 ◽  
Author(s):  
J. David Spence ◽  
Chrysi Bogiatzi ◽  
Mariya Kuk ◽  
George K. Dresser ◽  
Daniel G. Hackam
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Concomitant Medication ◽  
Antihypertensive Medication ◽  
Pressure Control ◽  
Blinded Study ◽  
History Of ◽  
Secondary Hyperaldosteronism ◽  
One Year ◽  
Resistance Score

Abstract Background and Objectives Resistant hypertension is an important problem; nearly half of diagnosed hypertensives are not controlled to target blood pressure levels, and approximately 90% of strokes occur among patients with resistant hypertension. Primary aldosteronism accounts for approximately 20% of resistant hypertension, but the role of secondary hyperaldosteronism in resistant hypertension is seldom considered. We assessed the effects of eplerenone in patients with hypertension and either primary or secondary hyperaldosteronism. Methods Patients with a history of resistant hypertension and a supine plasma aldosterone level ≥ 360 pmol/L were randomized to eplerenone versus placebo in a fully blinded study for one year. A medication intensity score was developed to assess the resistance of hypertension to medication (blood pressure × medication intensity). We assessed the effects of eplerenone on blood pressure and on resistance to concomitant medication. Results Final results were available in 37 patients (19 on eplerenone and 18 on placebo). Resistance to medication, as assessed by the intensity of concomitant medication required to maintain blood pressure control, was markedly reduced by eplerenone: medication intensity scores declined by –0.50 ± 1.04 (SD) on placebo versus –2.11 ± 1.45 with eplerenone (P = 0.0001), the Systolic Resistance Score declined by –80.00 ± 122.93 on placebo versus –334.05 ± 21.73 on eplerenone (P = 0.0001), and the Diastolic Resistance Score increased by 1.28 ± 31.65 on placebo and declined by –40.74 ± 57.08 on eplerenone (P = 0.009). Conclusions Eplerenone significantly reduced resistance to concomitant antihypertensive medication in both primary and secondary hyperaldosteronism.

scholarly journals Medication-induced SIADH: distribution and characterization according to medication class

2017 ◽  
Vol 83 (8) ◽  
pp. 1801-1807 ◽  
Author(s):  
Daniel Shepshelovich ◽  
Amir Schechter ◽  
Bronislava Calvarysky ◽  
Talia Diker-Cohen ◽  
Benaya Rozen-Zvi ◽  
...  
Keyword(s):  
Medication Class

scholarly journals Antibiotic Expenditures by Medication, Class, and Healthcare Setting in the United States, 2010–2015

2017 ◽  
Vol 66 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Katie J Suda ◽  
Lauri A Hicks ◽  
Rebecca M Roberts ◽  
Robert J Hunkler ◽  
Linda M Matusiak ◽  
...  
Keyword(s):  
United States ◽  
Healthcare Setting ◽  
The United States ◽  
Medication Class
Sign in / Sign up

Export Citation Format

Share Document